Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LNTH | PRESS-RELEASE | bullish | 7/10 | Lantheus received FDA approval for TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for evaluating Alzheimer's di | Aug 14, 2026 |
| HURA | 8-K | neutral | 3/10 | TuHURA Biosciences reported Q2 2026 financial results with cash of $1.0M and operating cash outflow of $13.0M in H1 2026 | Aug 14, 2026 |
| LNZA | 8-K | mixed | 6/10 | LanzaTech reported Q2 2026 revenue of $9.0M (flat YoY) but operating expenses dropped 67% to $11.7M, driving a 74% impro | Aug 14, 2026 |
| GALT | 8-K | bullish | 8/10 | Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headli | Aug 14, 2026 |
| CASIF | 6-K | bearish | 6/10 | CASI Pharmaceuticals reported H1 2026 results with revenue declining 5.8% to $9.8M, net loss narrowing to $20.0M from $2 | Aug 14, 2026 |
| TVRD | 8-K | mixed | 5/10 | Tvardi Therapeutics reported Q2 2026 EPS of $(0.69), a 6.2% miss vs consensus of $(0.65), with no revenue. The company a | Aug 14, 2026 |
| NMRA | 8-K | neutral | 4/10 | Neumora Therapeutics reported Q2 2026 results with a net loss of $43.1M ($0.23 per share), in line with consensus estima | Aug 14, 2026 |
| OTLK | PRESS-RELEASE | mixed | 7/10 | Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missing the consensus esti | Aug 14, 2026 |
| QNTM | 6-K | bullish | 7/10 | Quantum BioPharma reported Q2 2026 results showing improved liquidity (cash + digital assets of ~$9.5M, up from $4.1M) a | Aug 14, 2026 |
| RNTX | PRESS-RELEASE | bullish | 6/10 | Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating consensus of -$0.27 by 63%, driven by lower operating exp | Aug 14, 2026 |
| ANL | PRESS-RELEASE | bullish | 6/10 | Adlai Nortye reported H1 2026 results with revenue of $13.1M (from nil) from an AN9025 license agreement, net loss narro | Aug 14, 2026 |
| QNTM | PRESS-RELEASE | bullish | 7/10 | Quantum BioPharma reported Q2 2026 EPS of -$0.71, a 21% miss vs consensus of -$0.59, but the headline event is the FDA c | Aug 14, 2026 |
| NMRA | PRESS-RELEASE | neutral | 4/10 | Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalen | Aug 14, 2026 |
| TVRD | PRESS-RELEASE | mixed | 5/10 | Tvardi Therapeutics reported Q2 2026 EPS of -$0.73, a 15.6% miss vs consensus of -$0.63, with no revenue. Pipeline progr | Aug 14, 2026 |
| ACXP | PRESS-RELEASE | mixed | 5/10 | Acurx Pharmaceuticals reported Q2 2026 EPS of -$0.53, a 26% miss versus the $0.42 consensus, reflecting higher R&D spend | Aug 14, 2026 |
| FATE | PRESS-RELEASE | bullish | 5/10 | Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for | Aug 14, 2026 |
| ENLV | EFFECT | neutral | 4/10 | Enlivex Ltd.'s shelf registration statement (F-3) on Form 333-298071 was declared effective by the SEC on August 13, 202 | Aug 14, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma filed a 6-K announcing a conference call and webcast scheduled for August 14, 2026, with management partic | Aug 14, 2026 |
| BGMS | 8-K | bearish | 8/10 | BGMS reported Q2 2026 revenue of $336,000 (fire safety distribution) and a net loss of $405,000, improving from a $1.3M | Aug 14, 2026 |
| EIKN | 8-K | neutral | 3/10 | Eikon Therapeutics filed an 8-K on August 13, 2026, furnishing an updated corporate presentation (Exhibit 99.1) that hig | Aug 14, 2026 |
| MRK | CLUSTER | neutral | 2/10 | A cluster of insider selling at Merck (MRK) totaling ~$19.4M occurred in the 10 days following the Q2 2026 earnings rele | Aug 14, 2026 |
| AMRX | CLUSTER | bearish | 5/10 | Two senior executives at Amneal Pharmaceuticals (EVP Shah and EVP/CLO Daly) sold a combined $6.22M in open-market stock | Aug 14, 2026 |
| ZLAB | CLUSTER | neutral | 2/10 | Two Zai Lab insiders, including CFO Chen Yajing and Director Lis William, sold a combined $228K in open-market sales ove | Aug 14, 2026 |
| MEDP | CLUSTER | neutral | 3/10 | Medpace CEO August Troendle and a director sold a combined $11.35M in open-market sales over two days, with the CEO alon | Aug 14, 2026 |
| CYRX | INST-CLUSTER | bullish | 5/10 | Six institutional investors accumulated $42.8M in Cryoport (CYRX) during 2026-Q2, led by First Eagle Investment Manageme | Aug 14, 2026 |
| ELAN | CLUSTER | bullish | 4/10 | Three Elanco insiders, including CFO Robert VanHimbergen, purchased a total of $443K in open-market shares over the week | Aug 14, 2026 |
| XFOR | CLUSTER | neutral | 2/10 | Two top insiders at X4 Pharmaceuticals (Executive Chairman and President) sold a combined $320K in open-market transacti | Aug 14, 2026 |
| GEVO | CLUSTER | neutral | 4/10 | Four Gevo insiders (including CEO and CFO) sold a total of $466K in shares over a 7-day window, representing ~0.12% of m | Aug 14, 2026 |
| RCKT | CLUSTER | neutral | 3/10 | Two insiders at Rocket Pharmaceuticals, including the COO, sold a combined $145K in open-market sales on August 11, 2026 | Aug 14, 2026 |
| CRL | CLUSTER | neutral | 3/10 | A cluster of insider selling at Charles River Laboratories (CRL) totaling $10.21M occurred within 9 days of the Q2 2026 | Aug 14, 2026 |